Reprogramming of adult cells to generate induced pluripotent stem cells (iPS cells) has opened new therapeutic opportunities; however, little is known about the possibility of in vivo reprogramming within tissues. Here we show that transitory induction of the four factors Oct4, Sox2, Klf4 and c-Myc in mice results in teratomas emerging from multiple organs, implying that full reprogramming can occur in vivo. Analyses of the stomach, intestine, pancreas and kidney reveal groups of dedifferentiated cells that express the pluripotency marker NANOG, indicative of in situ reprogramming. By bone marrow transplantation, we demonstrate that haematopoietic cells can also be reprogrammed in vivo. Notably, reprogrammable mice present circulating iPS cells in the blood and, at the transcriptome level, these in vivo generated iPS cells are closer to embryonic stem cells (ES cells) than standard in vitro generated iPS cells. Moreover, in vivo iPS cells efficiently contribute to the trophectoderm lineage, suggesting that they achieve a more plastic or primitive state than ES cells. Finally, intraperitoneal injection of in vivo iPS cells generates embryo-like structures that express embryonic and extraembryonic markers. We conclude that reprogramming in vivo is feasible and confers totipotency features absent in standard iPS or ES cells. These discoveries could be relevant for future applications of reprogramming in regenerative medicine.
Reprogramming into pluripotency remains an intense field of investigation that is providing many insights about cellular plasticity 1,2 . Cellular reprogramming has been achieved under carefully controlled in vitro culture conditions 3 , whereas the in vivo tissue microenvironment is, in principle, conducive to cellular differentiation and opposed to reprogramming. However, we took note of remarkable examples in mice in which the normally irreversible state of cellular differentiation has been altered, inducing direct conversions in vivo from one cell type into a different one [4] [5] [6] [7] [8] [9] [10] . Encouraged by these precedents, we have attempted to achieve reprogramming in vivo.
Generation of reprogrammable mice
We have generated reprogrammable mice similar, but not identical, to others previously described [11] [12] [13] . A total of four transgenic mouse lines were obtained, each one carrying the transcriptional activator (rtTA) within the ubiquitously-expressed Rosa26 locus 14 and a single copy of a lentiviral doxycycline-inducible polycistronic cassette encoding the four murine factors Oct4 (also known as Pou5f1), Sox2, Klf4 and c-Myc 15 ( Fig. 1a ; Extended Data Fig. 1a ). In two of the four transgenic lines, the cassette was highly induced in most tissues (Extended Data Fig. 1b ) and mouse embryonic fibroblasts (MEFs) from these lines were efficiently reprogrammed in vitro upon addition of doxycyline (Extended Data Fig. 1c, d ). The other two transgenic lines did not express the cassette and their derived MEFs did not reprogram upon doxycycline addition. We have named the two functional transgenic lines as i4F-A and i4F-B, i4F standing for 'inducible four factors'. We determined the integration sites of the transgenes, which in the case of line i4F-A is within an intron of the Neto2 gene, and in the case of line i4F-B is within an intron of the Pparg gene (Extended Data Fig. 2a ). Transcription of these two genes remained unaltered in a number of tissues, either with or without doxycycline (Extended Data Fig. 2b ). We conclude that transgenic lines i4F-A and i4F-B contain a functional inducible reprogramming transgene that is expressed in most tissues without affecting the resident endogenous genes.
Reprogrammable mice generate teratomas
To test the possibility of in vivo reprogramming, we first treated i4F-A and i4F-B mice continuously with a high dose of doxycycline (1 mg ml 21 ) in the drinking water. This treatment resulted in weight loss and severe morbidity in both transgenic lines after 1 week. Histological examination of the mice revealed alterations in many tissues, particularly profound in the intestine and pancreas. The intestinal epithelium showed a generalized cytological and architectural dysplasia (Extended Data Fig. 3a) , probably responsible for the weight loss. A similar phenotype has been reported for mice with transgenic expression of Oct4 or c-Myc 14, 16 . In the case of the pancreas, mice presented multifocal dysplasia (Extended Data Fig. 3b ). Taking into account these observations, we tested two milder induction protocols that turned out to be compatible with the long-term survival of the mice. In particular, 2.5-week treatment with low doxycyline (0.2 mg ml 21 ) or 1-week treatment with high doxycycline (1 mg ml 21 ), both followed by doxycycline withdrawal. Remarkably, after a variable period of time, treated mice succumbed to the presence of tumoral masses ( Fig. 1b; Extended Data Fig. 4a ), most of which consisted of teratomas ( Fig. 1c; Extended Data Fig. 4b ). Teratomas are a particular class of tumours that originate from pluripotent cells after a process of expansion and disorganized differentiation. Most of the teratomas (32/45, 71%) were well differentiated and presented abundant examples of the three embryonic germ layers (Fig. 1d) . Therefore, the presence of teratomas in our reprogrammable mice is indicative of reprogramming into full pluripotency. Mice treated with the longinduction/low-doxycycline protocol developed teratomas faster and at a higher incidence rate than those treated with the short-induction/ high-doxycycline protocol (Fig. 1e) . The incidence of teratomas was higher in line i4F-A than in i4F-B (Fig. 1f) , and in both lines and protocols, teratomas appeared in a variety of organs (Fig. 1g) . Reprogrammable mice that were not treated with doxycycline remained healthy at least during 2 years of observation, indicating the absence of leaky expression of the reprogramming cassette. The presence of multiples teratomas in both lines implies that reprogramming into pluripotency is feasible within in vivo conditions.
In vivo reprogramming occurs in multiple tissues
Previous work has shown that haematopoietic progenitors can reprogram with high efficiency 17 . This, together with the broad distribution of haematopoietic cells within the organism, led us to consider that teratomas in our reprogrammable mice could originate from cells of the haematopoietic lineage. To address this, we performed bone marrow transplants into lethally irradiated hosts. In one setting, bone marrow (BM) from reprogrammable mice (i4F-BM) was transplanted into wild-type hosts and, in the reciprocal transplantation, wild-type bone marrow was transplanted into reprogrammable mice. Interestingly, both types of bone marrow reconstituted mice developed multiple teratomas upon induction (Fig. 2a, b) . These results suggest that haematopoietic and non-haematopoietic cells can both be reprogrammed in vivo. Of note, the teratomas present in i4F-BM transplanted mice were not emerging from organs, but outgrew attached to the serous membranes of the thoracic and abdominal cavities, whereas reprogrammable mice (either whole-body or transplanted with wild-type bone marrow) presented teratomas within multiple organs, as previously mentioned (Fig. 1g) .
The above results prompted us to look for early reprogramming events in non-haematopoietic cells. In particular, we focused on the stomach, intestine, pancreas and kidney of whole-body reprogrammable mice. We performed double immunohistochemistry against the epithelial marker cytokeratin 19 (CK19, also known as KRT19) and the pluripotency marker NANOG. We found aberrant individual gastric glands and intestinal crypts (in the small and large intestine) that had lost or decreased CK19 and expressed NANOG (Fig. 2c, d ). In some cases the entire gland or crypt was aberrant, whereas in others intermediate situations were found. In the pancreas, we observed both acinar-like (CK19-negative) and ductal-like (CK19-positive) structures with NANOG-positive cells (Fig. 2e ). In the kidney, which does not undergo major detectable morphological changes upon doxycycline induction but has a high incidence of teratomas (Fig. 1g) , we found isolated kidney tubules expressing NANOG (Extended Data  Fig. 4c ). In general, the number of reprogramming events evidenced 
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by NANOG (Fig. 2d) was clearly lower than the number of cells expressing the reprogramming cassette (Extended Data Fig. 3a) , implying that reprogramming in vivo is a low efficiency process that likely involves stochastic events, similar to what happens during in vitro reprogramming 18, 19 . The presence of isolated NANOG-positive structures, such as intestinal crypts or kidney tubules, probably reflects the clonal expansion of an individual reprogramming event. These observations support the concept that reprogramming occurs in situ, at least in the case of the epithelial cells of the stomach, intestine, pancreas and kidney.
Reprogrammable mice present iPS cells in the blood
Given the feasibility of in vivo reprogramming, we wondered whether it was possible to detect circulating iPS cells in the bloodstream. To address this, the cellular fraction of the blood from induced reprogrammable mice (,10 6 leukocytes) was seeded into plates with feeder fibroblasts and iPS cell culture medium (all procedures after blood extraction were performed in the absence of doxycycline). Remarkably, after a variable period of time (1-2 weeks), colonies with iPS cell morphology were visible (Fig. 3a) . These colonies were expanded (Fig. 3b) and were found to express pluripotency markers ( Fig. 3c, d ; Extended Data Fig. 5a ) and to have silenced the lentiviral reprogramming cassette (Extended Data Fig. 5b ). Moreover, in vivo iPS cells generated subcutaneous teratomas with representation of the three germ layers (Fig. 3e) , produced mouse chimaeras (Fig. 3f ) and contributed to the germ lineage (Extended Data Fig. 5c ). Therefore, we conclude that bona fide iPS cells can be isolated from the blood of reprogrammable mice. Of note, colonies of iPS cells were obtained from whole-body reprogrammable mice, as well as from wild-type mice with reprogrammable bone marrow and from reprogrammable mice with wild-type bone marrow (Extended Data Fig. 5d ). Therefore, both haematopoietic and non-haematopoietic cells can generate in vivo circulating iPS cells. The overall frequency of mice with colony-forming iPS cells was 6.5% (5/77) (Fig. 3g ), and this frequency was similar in the two transgenic lines (Extended Data Fig. 5d ). In those blood samples that were positive for iPS cells colony formation, the number of colonies obtained was variable (9 6 5) (Extended Data Fig. 5d ). We will refer to the circulating iPS cells as in vivo iPS cells to distinguish them from the standard in vitro generated ones.
Transcriptomic analysis of in vivo iPS cells
To further characterize the in vivo iPS cells, we performed messenger RNA deep sequencing. We sequenced in vivo iPS cells (n 5 6 independent clones), in vitro iPS cells (n 5 5 independent clones derived from i4F-MEFs) and ES cells (JM8. (Fig. 3h) . The same classification was obtained using principal component analysis, which is another unbiased method to quantify the degree of similarity between large data sets (Extended Data Fig. 6b ). The lists of differentially expressed genes were obtained for further analyses (Supplementary Tables 1-3 ). Interestingly, among the genes commonly upregulated in in vivo iPS and ES cells compared to in vitro iPS cells (a total of 51 genes; Supplementary Table 4) there were several pluripotency genes, including Gbx2, Lin28a, Utf1 and others associated with pluripotency, such as Epcam and Ccne1. The upregulation of these genes in in vivo iPS and ES cells was validated by quantitative PCR with reverse transcription (qRT-PCR) (Extended Data Fig. 7a ). Having established that in vivo iPS cells are extremely similar to ES cells, we focused on those few genes that were differentially expressed in in vivo iPS cells relative to ES cells and in vitro iPS cells ( Fig. 3i ; Supplementary Table 5) . Among these genes, we validated the upregulation of Nlrp4f (known to be enriched at the morula state) 22 , Etv4 (a transcription factor of the Ets family expressed during early development) 23 , Ppm1j (a protein phosphatase transcriptionally upregulated upon GSK3b inhibition) 24 , 8430410A17Rik (a gene consistently found associated with stemness) 25 and Tgm1 ( Fig. 3j; Extended Data Fig. 7b) , and the downregulation of Mmp12 and Tnc (both encoding components or regulators of the extracellular matrix) (Fig. 3j) . Importantly, the pattern of expression of these genes was similar in in vivo iPS cells and in morulas ( Fig. 3j ; Extended Data Fig. 7b ), thus suggesting that in vivo iPS cells and morulas share transcriptional features that are absent in ES cells or in in vitro iPS cells. We conclude that in vivo iPS cells are extremely similar to ES cells, but present differentially expressed genes that could conceivably confer additional properties to the in vivo iPS cells.
In vivo iPS cells contribute to the trophectoderm
We noted that the teratomas that appeared in reprogrammable mice often presented areas with large cells that resemble trophoblast giant RESEARCH ARTICLE cells associated with internal haemorrhages, altogether characteristic of placental tissue ( Fig. 4a ; see also examples in Figs 1d and 3e). Indeed, this was confirmed by the expression of PL-1 (placental lactogen 1 or chorionic somatomammotropin hormone 1) and CK8 (cytokeratin 8 or KRT8), which are both markers of trophoblast giant cells (Fig. 4a ). We were intrigued by this observation because trophoblast differentiation is rare in teratomas produced by ES cells 26 . To further explore this, we subjected ES cells, in vitro iPS cells and in vivo iPS cells to culture conditions that favour differentiation into trophoblast stem cells (namely, removal of LIF and addition of FGF4 and heparin) [26] [27] [28] . After 5 days, in vivo iPS cells formed abundant colonies with a flattened morphology characteristic of trophoblast stem cells. In contrast, in vitro iPS and ES cells produced a lower number of colonies and only few of them showed trophoblast stem cell like morphology (Fig. 4b) . Furthermore, in vivo iPS cells upregulated markers of trophectoderm lineage (Cdx2, Fgfr2 and Eomes) to a larger extent than equally treated in vitro iPS or ES cells ( Fig. 4c; Extended Data Fig. 8a ). The upregulation of Cdx2 in in vivo iPS cells was confirmed by immunofluorescence (Fig. 4d) . As a control, markers of ectoderm (Sox1), mesoderm (T) and endoderm (Gata6) lineages showed similar levels of expression among all the cell types examined (Extended Data Fig. 8a) . Moreover, upon removal of FGF4 and heparin, trophoblast stem cell differentiated in vivo iPS cells generated trophoblast giant cells (Fig. 4e) .
Based on the above observations, we tested the capacity of in vivo iPS cells to contribute to the trophectoderm. For this, GFP-expressing in vivo iPS and ES cells were aggregated or microinjected into morulas (either wild type or carrying a Katushka red fluorescent transgene 29 ) and the resulting blastocysts were examined. As expected, both cell types, in vivo iPS and ES cells, efficiently contributed (100%) to the inner cell mass (ICM). Interestingly, in vivo iPS cells also contributed to the polar trophectoderm (surrounding the ICM) and to the mural trophectoderm ( Fig. 4f; Extended Data Fig. 8b) . Altogether, in vivo iPS cells contributed to the trophectoderm with a remarkable efficiency (56%), which was in contrast to ES cells (0%) (Fig. 4g) 
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. To test whether the in vivo iPS cells actually contribute to the formation of the placenta, we examined chimaeric E14.5 embryos generated with GFP-expressing in vivo iPS cells and we observed a high degree of chimaerism both in the embryo proper as well as in the placenta (Fig. 4h, i Data Fig. 9 ). Therefore, in vivo iPS cells do not seem to be enriched in the 2C state, although, as shown above (Fig. 3j) , they share transcriptional features with morulas. Together, we conclude that in vivo reprogramming confers a pluripotency state that, in contrast to ES cells or standard in vitro iPS cells, can readily access the trophectodermal lineage.
In vivo iPS cells generate embryo-like structures
During the course of the above analyses we observed the presence of small cysts in the thoracic and abdominal cavities of two reprogrammable mice (from a total of 77 induced reprogrammable mice) (Fig. 5a ). These cysts were often detached from the surrounding organs and from the lining of the abdominal and thoracic cavities (Fig. 5a) . The cysts were formed by membranous structures and, based on their detailed characterization (see below), we refer to them as embryo-like structures. We wondered whether in vivo iPS cells could also form embryo-like structures when injected intraperitoneally into wild-type mice. Remarkably, in addition to the expected teratomas, a fraction of mice injected with in vivo iPS cells contained embryo-like structures, in contrast to the mice injected with in vitro iPS or ES cells (Fig. 5b) . Immunohistological analyses of the embryo-like structures indicated the presence of cell layers and cellular areas expressing lineage markers SOX2 (ectoderm), T/BRACHYURY (mesoderm), or GATA4 (endoderm) ( Fig. 5c; Extended Data Fig. 10 ). In addition, these embryo-like structures also expressed CDX2 ( Fig. 5c; Extended Data Fig. 10 ), indicative of trophectoderm lineage 32 , and presented cell layers with the typical border morphology of the yolk sac endoderm which co-expressed a-fetoprotein (AFP) and cytokeratin 8 (CK8) ( Fig. 5c ; Extended Data Fig. 10 ), both characteristic of the visceral endoderm of the yolk sac 33 . Finally, embryo-like structures presented regions resembling blood islands, internally lined by the endothelial cell surface marker LYVE-1 (ref. 34 ) and with associated nucleated erythrocytes positive for the TER-119 marker (Fig. 5d) , highly suggestive of yolk sac associated erythropoiesis. We conclude that in vivo iPS cells possess an unprecedented cell-autonomous capacity to produce embryo-like structures containing the three embryonic germ layers together with structures reminiscent of the extraembryonic ectoderm and the yolk sac. This reinforces the concept that in vivo reprogramming allows the acquisition of totipotency features that are absent in ES cells or in standard in vitro reprogrammed iPS cells.
Conclusion
In this work, we demonstrate that the four factors Oct4, Sox2, Klf4 and c-Myc can induce dedifferentiation and pluripotency in a variety of cell types in vivo, including cells from the haematopoietic lineage, as 
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well as epithelial cells from the stomach, intestine, pancreas and kidney. In the context of previous examples of in vivo cellular conversions [4] [5] [6] [7] [8] [9] [10] , our results notably extend the concept of in vivo plasticity to many tissues and to the extreme case of generating embryonic pluripotent cells, a cell type that is absent in the adult organism. Previous investigators have shown that intentionally incomplete in vitro reprogramming with the four factors triggers a dedifferentiated cellular state that can have advantageous differentiation properties 35, 36 . In this regard, partial or transient activation of the four factors in vivo is an attractive approach for regenerative purposes.
Another important aspect of our work is the recovery of circulating iPS cells from the blood of induced reprogrammable mice, which can derive from both haematopoietic and non-haematopoietic cells. Notably, in vivo iPS and ES cells are extremely similar, and clearly separated from in vitro iPS cells. Despite the high similarity between in vivo iPS and ES cells, it is possible to detect differentially expressed genes among the two cell types. These differences may originate from differential epigenetic marks and/or self-sustained transcriptional networks, both of which are prominent regulators of pluripotency 37, 38 . In vivo iPS cells present a remarkable capacity to undergo trophectoderm lineage differentiation, a property that is largely absent in ES cells (or in vitro iPS cells) under normal culture conditions. Finally, in vivo iPS cells have an unprecedented capacity to form embryo-like structures, including the three germ layers of the proper embryo and extraembryonic tissues, such as extraembryonic ectoderm and yolk sac like tissue with associated embryonic erythropoiesis. Together, we conclude that in vivo iPS cells represent a more primitive or plastic state than ES cells. Future work will explore the full capabilities of in vivo iPS cells.
METHODS SUMMARY
In vivo iPS cell isolation. Peripheral blood (0.3-0.5 ml) was collected directly from the heart of doxycycline-induced i4F mice at the time of necropsy. After blood extraction, all procedures were performed in the absence of doxycycline. The recovered cells were plated on feeders and cultured in iPS cell medium. Generation of embryo-like structures. Wild-type C57BL/6 mice were injected with 5 3 10 5 cells in 100 ml of iPS cell medium. When teratomas were palpable, usually around 2 months post-injection, mice were euthanized.
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METHODS
Generation of i4F reprogrammable mice. To generate reprogrammable mice, we transduced C57BL/6 mouse embryonic fibroblasts (MEFs) carrying a doxycycline-inducible transcriptional activator (rtTA) within the Rosa26 locus 14 (generously provided by K. Hochedlinger) with a lentivirus carrying a doxycyclineinducible tetracistronic cassette with the four murine reprogramming factors (Oct4, Sox2, Klf4, c-Myc) 15 (Tet-O-FUW-OSKM, obtained from Addgene #20321). After lentiviral transduction, MEFs were treated with 1 mg ml 21 of doxycycline and colonies of iPS cells appeared after 1 week. Several iPS cells colonies were picked, expanded and microinjected into albino C57BL/6J-Tyr c-2J /J E3.5 blastocysts (5-7 iPS cells per blastocyst) to obtain chimaeras. Chimaeric mice were backcrossed with C57BL6/J mice until the lentiviral transgenes were transmitted at Mendelian proportions (indicative of single integration site). The resulting reprogrammable i4F mice used in this study are in a pure C57BL6/J genetic background. Southern blotting. Genomic DNA (tail tip) was digested overnight with BamHI and hybridized with probes designed to recognize exonic sequences of Sox2 and Klf4. The probes were generated by PCR of genomic DNA with the following primers: Sox2-F: 59-TACAGCATGATGCAGGAGCA-39; Sox2-R: 59-CTGGG CCATGTGCAGTCTAC-39; Klf4-F: 59-CAGCTTCAGCTATCCGATCC-39; Klf4-R: 59-CGCCTCTTGCTTAATCTTGG-39. Transgene insertion site determination. We performed gene walking as described 39 . Insertion sites were confirmed by PCR using primers against genomic sequences around the insertion site (Neto2 in the case of line i4F-A, primer 59-GCGTCA GGCAATTTATACTCTGG-39; and Pparg in the case of line i4F-B, primer 59-CA GCATCAAATGGCTCGGTA-39) and against the lentiviral transgene (59-GCAC CATCCAAAGGTCAGTG-39). Animal procedures. Animal experimentation at the CNIO, Madrid, was performed according to protocols approved by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA). Doxycycline (Sigma) was administered in the drinking water supplemented with 7.5% of sucrose. Experiments were performed indistinguishably with mice of both sexes and from 2 to 6 months of age. For bone marrow (BM) transplant, groups of 8 wild-type mice (C57BL6/J, 8-10-weeks old) per donor mouse were irradiated with 12 Gy. The following day, the bone marrow of the donor mice was harvested from the femora and tibiae and 2 3 10 6 -2.5 3 10 6 cells, suspended in Leibovitz medium (Sigma, L5520), were intravenously injected per recipient. Experiments on transplanted mice were performed after a latency of at least 30 days to ensure BM reconstitution. For the intraperitoneal injections, wild-type mice were injected with 5 3 10 5 cells suspended in 100 ml of iPS cell medium. For subcutaneous teratomas, iPS or ES cells were trypsinized and 2 3 10 6 cells were subcutaneously injected into the flanks of immunocompromised nude mice (Swiss nude from Charles River). Teratomas were isolated when the diameter reached .1.5 cm and processed for histological analysis. ) cells with Tet-O-FUW-OSKM (Addgene #20321) and packaging vectors using Fugene HD (Roche). Viral supernatants were collected twice a day on two consecutive days starting 24 h after transfection and were used to infect ROSA26-rtTA MEFs, previously plated at a density of 2 3 10 5 cells per well in 6-well plates. Previous to infection, polybrene was added to the viral supernatants at a concentration of 8 mg ml 21 . For in vitro i4F reprogramming, i4F MEFs were plated at a density of 5 3 10 5 cells per well in 6-well gelatin-coated plates, and at a density of 3 3 10 5 for the kinetics assay. Infected MEFs or i4F-MEFs were cultured in iPS cell medium with doxycycline (1 mg ml
21
). Medium was changed every 48 h until iPS cell colonies appeared (after ,7 days of treatment). Reprogramming plates were stained for alkaline phosphatase activity (AP detection kit, Sigma-Aldrich). When indicated, ES cells or in vivo iPS cells were retrovirally infected with a vector expressing GFP (pMSCV-PIG) and infected cells were sorted by FACS. In vivo iPS cell isolation. Peripheral blood (0.3-0.5 ml) was collected directly from the heart of i4F mice at the time of necropsy, and was subjected to two rounds of erythrocyte lysis in ammonium chloride solution (Stem Cells). First round of lysis with 10 ml, for 15 min at room temperature, followed by centrifugation, and a second round of lysis with 3 ml, for 15 min at room temperature, followed by neutralization with 12 ml of iPS cell medium. Cells were pelleted and counted, recovering ,10 6 cells per mouse. Cells were resuspended, plated on feeders and cultured in iPS cell medium.
Immunofluorescence. Cells previously seeded in cover slips were fixed in 4% paraformaldehyde for 20 min, permeabilized (PBS 0.1% Triton X-100) for 15 min and blocked in FBS, for 1 h at room temperature. For the detection of OCT4 we used two antibodies with similar results, BD 611203, dilution 1:200, and Santa Cruz sc-5279, dilution 1:400; for NANOG, Novus NB100 58842, dilution 1:50; and for CDX2, Epitomics #2475-1, dilution 1:400. Cells were inspected under a Leica SP5 microscope equipped with white light laser and hybrid detection. Chimera generation and germline contribution. For chimaera generation, in vivo iPS cells (5-7 cells per embryo, ,10 passages) were microinjected into C57BL/6J-Tyr c-2J
/J blastocysts and transferred to Crl:CD1 (ICR) pseudopregnant females. To study the contribution to germline, GFP-infected in vivo iPS cells (,14 passages) were similarly microinjected into blastocysts and the gonads from chimaeric male E14.5 embryos were isolated, fixed in 4% paraformaldehyde, and analysed for GFP fluorescence in whole mount with laser scanning confocal microscope SP5 from Leica, equipped with white light laser and hybrid detection. Lens used for imaging were 320 (dry lens) 0.7 numerical aperture and 363 (water lens) with a 1.2 numerical aperture. , using the mouse genome annotation data set GRCm38/mm10 from the UCSC Genome Browser. Trophectoderm stem cell differentiation. ES and iPS cells (all with ,10 passages) were plated on feeders (7 3 10 4 cells per well in 6-well plates) in iPS cells medium and 24 h later medium was changed into TS differentiation medium that contained the following components: 3 volumes of RPMI 1640 (with 20% FBS, 1 mM pyruvate, 2 mM L-glutamine, 100 mM b-mercaptoethanol), 7 volumes of conditioned medium from mitomycin-C-inactivated fibroblasts, 25 pg ml 21 of FGF4 (R&D Systems, 235-F4-025) and 1 mg ml 21 of heparin (Sigma, H3149). Medium was changed every other day, and all cells were split once at day 2. For giant cell differentiation, trophoblast stem cell differentiated in vivo iPS cells and established trophoblast stem cells were plated on gelatine and cultured in RPMI 1640 (with 20% FBS, 1 mM pyruvate, 2 mM L-glutamine, 100 mM b-mercaptoethanol) in the absence of heparin and FGF4 for 3 days. Analysis of trophectoderm lineage contribution. GFP-labelled ES cells or in vivo iPS cells (5-7 cells, all with ,14 passages) were aggregated or microinjected into 8-cell stage embryos using standard techniques 43 . Morulas were incubated overnight and observed under the confocal microscope in KSOM (Chemical International) microdrops under mineral oil. In some cases Tg.CAG-Katushka embryos 29 were used as recipients. To study the contribution of GFP-in vivo iPS cells to the placenta, blastocysts were transferred to pseudopregnant females and embryos (E14.5) with their placentas were collected in PBS and observed directly under a fluorescence-equipped stereomicroscope or fixed for immunostaining. Analysis of mRNA levels. Total RNA was extracted from cell or tissue samples with Trizol (Invitrogen), following provider's recommendations and retrotranscribed into cDNA following the manufacturer's protocol (Maxima First Strand cDNA systhesis Kit for RT-qPCR, Fermentas). Quantitative real time-PCR was performed using Syber Green Power PCR Master Mix (Applied Biosystems) in an ABI PRISM 7700 thermocycler (Applied Biosystem). For input normalization, we used the housekeeping genes Actb (b-actin) or Gapdh. The primers used were: Actb forward primer: 59-GGCACCACACCTTCTACAATG-39, Actb reverse primer: 59-GTGGTGGT GAAGCTGTAGCC-39; Ccne forward primer: 59-GTGGCTCCGACCTTTCAG TC-39, Ccne reverse primer 59-CACAGTCTTGTCAATCTTGGCA-39; Cdx2 forward primer 59-CAAGGACGTGAGCATGTATCC-39, Cdx2 reverse primer 59-GTAACCACCGTAGTCCGGGTA-39; E2A-c-Myc forward primer, 59-GGCTG GAGATGTTGAGAGCAA-39, E2A-c-Myc reverse primer 59-AAAGGAAATCC AGTGGCGC-39; Eomes forward primer 59-TTCACCTTCTCAGAGACACAGT TCAT-39, Eomes reverse primer 59-GAGTTAACCTGTCATTTTCTGAAGCC-39; Epcam forward primer 59-GCGGCTCAGAGAGACTGTG-39, Epcam reverse primer 59-CCAAGCATTTAGACGCCAGTTT-39; Etv4 forward primer, 59-TGGTGAT CAAACAGGAGCG-39, Etv4 reverse primer, 59-GGGTGGAGGTACATTGA TGC-39; Fgfr2 forward primer, 59-GAGGAATACTTGGATCTCACC-39, Fgfr2 reverse primer 59-CTGGTGCTGTCCTGTTTGGG-39; Gapdh forward primer RESEARCH ARTICLE
